A hybrid model to evaluate the impact of active uptake transport on hepatic distribution of atorvastatin in rats

References

• Ambudkar SV, Dey S, Hrycyna CA, et al. (1999). Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual Rev Pharmacol Toxicol 39:361–98.
   PubMed Web of Science ®Google Scholar
• Brenner S, Riha J, Giessrigl B, et al. (2015). The effect of organic anion-transporting polypeptides 1B1, 1B3 and 2B1 on the antitumor activity of flavopiridol in breast cancer cells. Int J Oncol 46:324–32.
   PubMed Web of Science ®Google Scholar
• Chang JH, Ly J, Plise E, et al. (2014). Differential effects of Rifampin and Ketoconazole on the blood and liver concentration of atorvastatin in wild-type and Cyp3a and Oatp1a/b knockout mice. Drug Metab Dispos 42:1067–73.
   PubMed Web of Science ®Google Scholar
• Chen C, Mireles RJ, Campbell SD, et al. (2005). Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 33:537–46.
   PubMed Web of Science ®Google Scholar
• Chu X, Korzekwa K, Elsby R, et al. (2013). Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin Pharmacol Ther 94:126–41.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5.
   PubMed Web of Science ®Google Scholar
• De Bruyn T, Ufuk A, Cantrill C, et al. (2018). Predicting human clearance of OATP substrates using cynomolgus monkey: in vitro-in vivo scaling of hepatic uptake clearance. Drug Metab Dispos 46:989.
   PubMed Web of Science ®Google Scholar
• DeGorter MK, Urquhart BL, Gradhand U, et al. (2012). Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. J Clin Pharmacol 52:1689–97.
   PubMed Web of Science ®Google Scholar
• Di L, Atkinson K, Orozco CC, et al. (2013). In vitro-in vivo correlation for low-clearance compounds using hepatocyte relay method . Drug Metab Dispos 41:2018–23.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–36.
   PubMed Web of Science ®Google Scholar
• Gur E, Waner T. (1993). The variability of organ weight background data in rats. Lab Anim 27:65–72.
   PubMed Web of Science ®Google Scholar
• Higgins JW, Bao JQ, Ke AB, et al. (2014). Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein. Drug Metab Dispos 42:182–92.
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, et al. (2004). Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139–46.
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, et al. (2006). Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34:1229–36.
   PubMed Web of Science ®Google Scholar
• Hochman JH, Pudvah N, Qiu J, et al. (2004). Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res 21:1686–91.
   PubMed Web of Science ®Google Scholar
• Hsiang B, Zhu Y, Wang Z, et al. (1999). A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274:37161–8.
   PubMed Web of Science ®Google Scholar
• Izumi S, Nozaki Y, Maeda K, et al. (2015). Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions. Drug Metab Dispos 43:235–47.
   PubMed Web of Science ®Google Scholar
• Karlgren M, Vildhede A, Norinder U, et al. (2012). Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem 55:4740–63.
   PubMed Web of Science ®Google Scholar
• Kearney AS, Crawford LF, Mehta SC, et al. (1993). The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm Res 10:1461–5.
   PubMed Web of Science ®Google Scholar
• Knipp GT, Ho NF, Barsuhn CL, et al. (1997). Paracellular diffusion in Caco-2 cell monolayers: effect of perturbation on the transport of hydrophilic compounds that vary in charge and size. J Pharm Sci 86:1105–10.
   PubMed Web of Science ®Google Scholar
• Korzekwa KR, Nagar S, Tucker J, et al. (2012). Models to predict unbound intracellular drug concentrations in the presence of transporters. Drug Metab Dispos 40:865–76.
   PubMed Web of Science ®Google Scholar
• Kulkarni P, Korzekwa K, Nagar S. (2016). Intracellular unbound atorvastatin concentrations in the presence of metabolism and transport. J Pharmacol Exp Ther 359:26–36.
   PubMed Web of Science ®Google Scholar
• Kunze A, Huwyler J, Camenisch G, et al. (2014). Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data. Drug Metab Dispos 42:1514–21.
   PubMed Web of Science ®Google Scholar
• Lau YY, Okochi H, Huang Y, et al. (2006a). Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Therap 316:762–71.
   PubMed Web of Science ®Google Scholar
• Lau YY, Okochi H, Huang Y, et al. (2006b). Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 34:1175–81.
   PubMed Web of Science ®Google Scholar
• Lugo MR, Sharom FJ. (2005). Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site. Biochemistry 44:643–55.
   PubMed Web of Science ®Google Scholar
• Maeda K, Ieiri I, Yasuda K, et al. (2006). Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 79:427–39.
   PubMed Web of Science ®Google Scholar
• Maeda K, Ikeda Y, Fujita T, et al. (2011). Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 90:575–81.
   PubMed Web of Science ®Google Scholar
• Menochet K, Kenworthy KE, Houston JB, et al. (2012a). Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. J Pharmacol Exp Ther 341:2–15.
   PubMed Web of Science ®Google Scholar
• Menochet K, Kenworthy KE, Houston JB, et al. (2012b). Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. Drug Metab Dispos 40:1744–56.
   PubMed Web of Science ®Google Scholar
• Morse BL, Alberts JJ, Posada MM, et al. (2019). Physiologically‐based pharmacokinetic modeling of atorvastatin incorporating delayed gastric emptying and acid‐to‐lactone conversion. CPT: Pharma Syst Pharmacol. https:/doi.org/10.1002/psp4.12447.
   Google Scholar
• Pang KS, Durk MR. (2010). Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. J Pharmacokinet Pharmacodyn 37:591–615.
   PubMed Web of Science ®Google Scholar
• Pang KS, Yang QJ, Noh K. (2017). Unequivocal evidence supporting the segregated flow intestinal model that discriminates intestine versus liver first-pass removal with PBPK modeling. Biopharm Drug Dispos 38:231–50.
   PubMed Web of Science ®Google Scholar
• Partani P, Verma SM, Gurule S, et al. (2014). Simultaneous quantitation of atorvastatin and its two active metabolites in human plasma by liquid chromatography/(-) electrospray tandem mass spectrometry. J Pharm Anal 4:26–36.
   PubMedGoogle Scholar
• Patilea‐Vrana G, Unadkat JD. (2016). Transport vs. metabolism: what determines the pharmacokinetics and pharmacodynamics of drugs? Insights from the extended clearance model. Clin. Pharmacol. Ther 100:413–8.
   PubMed Web of Science ®Google Scholar
• Quinney SK, Zhang X, Lucksiri A, et al. (2009). Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos 38:241–8.
   PubMed Web of Science ®Google Scholar
• Richardson PD, Withrington PG. (1982). Physiological regulation of the hepatic circulation. Ann Rev Physiol 44:57–69.
   PubMed Web of Science ®Google Scholar
• Roth M, Araya JJ, Timmermann BN, et al. (2011). Isolation of modulators of the liver-specific organic anion-transporting polypeptides (OATPs) 1B1 and 1B3 from Rollinia emarginata Schlecht (Annonaceae). J Pharmacol Exp Ther 339:624–32.
   PubMed Web of Science ®Google Scholar
• Shitara Y, Horie T, Sugiyama Y. (2006). Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425–46.
   PubMed Web of Science ®Google Scholar
• Shitara Y, Maeda K, Ikejiri K, et al. (2013). Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos 34:45–78.
   PubMed Web of Science ®Google Scholar
• Sohlenius-Sternbeck A-K. (2006). Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements. Toxicol In Vitro 20:1582–6.
   PubMed Web of Science ®Google Scholar
• Sun H, Pang KS. (2010). Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates. Pharm Res 27:1237–54.
   PubMed Web of Science ®Google Scholar
• Varma MV, Lai Y, Feng B, et al. (2012). Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res 29:2860–73.
   PubMed Web of Science ®Google Scholar
• Verbeeck RK, Singu BS, Kibuule D. (2019). Clinical significance of the plasma protein binding of rifampicin in the treatment of tuberculosis patients. Clin Pharma. https://doi.org/10.1007/s40262-019-00800-1
   Google Scholar
• Vildhede A, Karlgren M, Svedberg EK, et al. (2014). Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions. Drug Metab Dispos 42:1210–8.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Maeda K, et al. (2009a). Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos 38:215–22.
   Google Scholar
• Watanabe T, Kusuhara H, Maeda K, et al. (2009b). Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652–62.
   PubMed Web of Science ®Google Scholar
• Zhang X, Galinsky RE, Kimura RE, et al. (2010). Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats. Drug Metab Dispos 38:61–72.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Gallo JM. (2011). The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic. AAPS J 13:111–20.
   PubMed Web of Science ®Google Scholar